Evidence map›Paper›PMID 36130981›Full record

ArticleScientific reports2022

Diagnostic features and management options for duodenal neuroendocrine neoplasms: a retrospective, multi-centre study.

Dalvinder Mandair, Lukasz Kamieniarz, Michail Pizanias, Martin O Weickert, Akshay Narayan, Luke Furtado O'Mahony, Martyn Caplin, John Ramage, Andreas Prachalias, Rajaventhan Srirajaskanthan and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Nonexposure full-thickness resection in a laparoscopic-endoscopic approach as a hybrid technique for nonampullary duodenal neuroendocrine tumor.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2025
    Article
  3. Long-Term Outcomes in Patients With Non-Ampullary Duodenal Neuroendocrine Tumors.The Korean journal of helicobacter and upper gastrointestinal research · 2025
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Dalvinder MandairNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, NW3 2QG, UK. dalvinder.mandair@nhs.net.
Lukasz KamieniarzUniversity College Medical School, London, UK.
Michail PizaniasNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Institute of Liver Studies, Kings College Hospital, London, UK.
Martin O WeickertThe ARDEN NET Centre, ENETS CoE, University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, Coventry, CV2 2DX, UK.
Akshay NarayanUniversity College Medical School, London, UK.
Luke Furtado O'MahonyUniversity College Medical School, London, UK.
Martyn CaplinNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, NW3 2QG, UK.
John RamageNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Institute of Liver Studies, Kings College Hospital, London, UK.
Andreas PrachaliasDepartment of Hepatobiliary Surgery, Institute of Liver Studies, Kings College Hospital, London, UK.
Rajaventhan SrirajaskanthanNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Institute of Liver Studies, Kings College Hospital, London, UK.
Christos ToumpanakisNeuroendocrine Tumour Unit, ENETS Centre of Excellence, Royal Free Hospital, London, NW3 2QG, UK.
University College London · GBKing's College Hospital · GBKing's College London · GBUniversity Hospitals Coventry and Warwickshire NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duodenal neuroendocrine neoplasms (dNENs) are rare neoplasms but their incidence is on the rise. They are classified into 5 sub-types but there remains much heterogeneity in behaviour in particular of non-functioning dNENs. To retrospectively analyse outcomes for all types of dNENs, and highlight prognostic factors associated with worse outcome. 102 (57 m/45f.) patients were identified with mean age at diagnosis 62 (range 32-87) years. The majority were non-functioning tumours 87/102 and median size was 10 mm (range 0.9-130 mm). 83 patients had Stage I or II disease, of which 17 underwent endoscopic resection with R1 rate of 45% and complication rate 12%. 36 patients were kept under endoscopic surveillance. There were 11 deaths of which 4 were disease related. Age and Ki67 > 20% were associated with worse OS in all dNENs. In non-functioning dNENs Ki67 > 3% was a predictor of lymph nodes metastases with OR 18.2 (2.54-13) (p < 0.005) in univariate analyses and liver metastases with OR 6.79 (1.56-29.5) (p < 0.05) in the multivariate analysis. Lesions 11-20 mm in size had OR 11.1 (1.16-106) compared to lesions < 11 mm for the prediction of lymph node metastases in the multivariate analysis (p < 0.05). ROC analysis of size of non-functioning dNENs to predict LN metastases found < 15 mm had an AUROC of 0.9 (0.81-0.99) with a sensitivity of 85% and specificity of 88%. dNENs are increasing in incidence, however low grade and smaller lesions have an indolent course and the role of endoscopic resection and active surveillance needs to be reviewed.

Indexed as

Duodenal NeoplasmsNeuroendocrine TumorsPancreatic NeoplasmsAdultAgedAged, 80 and overHumansKi-67 AntigenLymphatic MetastasisLymph NodesMiddle AgedPrognosisRetrospective StudiesKi-67 Antigen

Identifiers

PMID36130981
PMCPMC9492724
OpenAlexW4296691004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.